《滬深兩市》上證平收 深成全日微微倒升 內房股走高 寧德時代跌逾3%
內地昨日(20日)新增本土確診病例71例。人民銀行公佈,一年期及五年期LPR維持不變,利率持平於3.7%及4.6%,今日(21日)進行100億元人民幣(下同)7天期逆回購操作,單日零投放零回籠。人民幣兌美元中間價今下調58點。地緣政治局勢仍然緊張,上證深成創板開市個別發展後齊齊回軟。上證及深成午後近尾市受內房股走高帶動回穩。
上證平收報3,490點;深成指微升11點或0.09%,收報13,471點;創業板指數則跌22點或0.8%,收報2,804點,成交2,275.5億元。上證深成成交較上日縮減,全日成交分別爲3,454億元及5,551億元。
中資金融股窄幅走個別,工行(601398.SH)及建行(601939.SH)分別升0.2%及跌0.5%。中移動(600941.SH)回升1.2%。據報中電信(601728.SH)將加大在國家樞紐節點數據中心建設,惟股價跌1.6%。
上月70個大中城市新建商品住宅和二手住宅銷售價格按月降幅減弱,按年漲幅回落,加上,內地四大國有銀行下調廣州地區房貸利率,消息帶動地產股走高,大悅城(000031.SZ)揚7%。萬科A(000002.SZ)、金地集團(600383.SH)及陽光城(000671.SZ)升1%至1.3%。
煤電股逆市上升,山西焦煤(000983.SZ)揚8.3%。甘肅電投(000791.SZ)漲停。
白酒股有資金吸納,金種子酒(600199.SH)漲停。大豪科技(603025.SH)揚8.4%。
據報內地「十四五」新型儲能發展規劃即將出臺,刺激儲能概念股午後走強,英維克(002837.SZ)漲停。科華數據(002335.SZ)揚7.7%。
國家衛健委表示,康希諾生物(688185.SH)及智飛生物(300122.SZ)新冠病毒疫苗獲批用於序貫加強免疫接種,兩股今升1.9%及0.3%。
比亞迪(002594.SZ)元PLUS訂單量突破兩萬臺,澳洲正式預售,股價跌0.4%。寧德時代(300750.SZ)低開低走跌3.3%。(ta/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.